06 November 2018
By Dr Wendy Winnall - PCFA Research Team
A key US patent for the use of Abiraterone (Zytiga) for treating metastatic prostate cancer has been ruled invalid by a US court. This could lead to cheaper versions of Abiraterone becoming available in the US. This sounds like great news for US patients. This week’s blog explores the pharmaceutical industry behind prostate cancer drugs and what this new development means for Australian patients.
To read the full article just log into the PCFA Online Community.
If you're not already a member, it is free and easy to join.
